Phosphagenics - e-Updates

Home
About Us
	Company Overview
	Strategy
	Technology and IP
	Management
	Board
	Scientific Advisors
	History
	Collaborations & Partners
	Publications
Pharmaceuticals
	Overview
	Drug Delivery
	TPM-01
	TPM-02
	Drug Enhancement
	APA-01
	GTP-0805
	R&D Pipeline
Nutraceuticals
	Overview
	Phospha E
	Product Development
Investors
	Overview
	Board
	Corporate Governance
	Financial Reports
	Presentations
	Company Announcements
	AIM
	Shareholder Information
News
	Transdermal diclofenac enters clinic
	Metabolic Syndrome Trial Recruitment
	Phase 1 transdermal lidocaine trial commencement
	AIM Update
	US non executive director
	AGM Results
	AGM Chairman and CEO's address
	Phosphagenics executive appointment
	Positive pre-clinical lidocaine results
	Phosphagenics Initiates trial in Type 1 Diabetes
	GRAS Status - Phospha E
	2007 Financial Report Appendix 4E
	Initiation of retinoic acid clinical trial
	Progression of Phosphagenics and Nestle trial
	Superior preclinical cholesterol results APA-01
	Successful oxycodone clinical trial results
	Dietary Supplement Update
	Phospha E phase 2 trial
	Phase 1 oxycodone trial approved
	Phosphagenics to conduct Phase 1 oxycodone trial
	Phosphagenics to commence phase 2 insulin trial
	Positive Phase 1b transdermal insulin
	Phosphagenics lists on OTCQX
	Phosphagenics and Nestle extend option agreement
	Phosphagenics information available through S&P
	Dermal Delivery Breakthrough
	Phosphagenics awarded a $2.1m AusIndustry Grant
	AGM - Chairman's Address
	Phase 1b insulin clinical trial commenced
	AusIndusty offers Phosphagenics P3 grant
	Phosphagenics to commence insulin trial in May
	2006 Annual Report
	Phosphagenics' presentation: Cowen conference
	Phosphagenics to present at Cowen Conference
	Transdermal technology platform extended
	2007 Financial Report
	Nestle exercises option to commercialise Phospha E
	Nestle enters commerical discussions with Phos...
	Phospha E preclinical trials with Nestlé Nutrition
	Share Placement and Share Purchase Plan offer
	Completion of Transdermal Insulin Trial
	Phosphagenics Assigns Phospha E Licence
	Tox results support broadening TPM-01/M program
	Anticancer Agent Reduces Breast Tumour Growth
	Half Yearly Results
	Phosphagenics Signs Agreement with Major Cosmetic
	Insulin Successfully Delivered Across The Skin
	Commencement Of Phase I Clinical Trials...
	Ethics Approval for Phase I Clinical Trials of...
	Positive Preclinical Trial Results Of...
	Plans To Expand Manufacturing Capabilities
	Phase 2a Clinical Trial of Transdermal Morphine...
	Phosphagenics and Nestlé Nutrition Sign Agreement
	2005 Annual Report
	American Depository Receipt Program Established
	Phosphagenics Financial Yearly Report 2005
	Animal Trials Of Anti-Cancer Compound GTP-0805...
	Phase 1b Transdermal Morphine Gel Trial Successful
	Phosphagenics Announces $A11.25 Million Share...
	Phosphagenics Signs Development Agreement
	Second Study Links Phospha E...
	Appointment of Dr Ogru as Executive Director...
	Transdermal Delivery of Insulin - Study Summary
	Transdermal Delivery of Insulin
	Release of Half Year Results
	Peptide Results Extend Platform Technology
	Successful Morphine Phase I Clinical Trial
	Animal Trial Shows New Drug Reduces...
	Swisse Vitamins Agreement
	Phospha E Reduces Animal Cholesterol Levels
	AusIndustry Start Grant
	Major Global Pharmaceutical Company Endorses...
	Baker Heart Research Institute Alliance
	International Heart Disease Prevention Trials
	POH Meets with US FDA to Discuss Development...
	Australian Patented Vitamin E on Sale in US
	Scientific Advisory Board
	POH to Seek UK Listing on AIM
	Phosphagenics' World First in Heart Treatment
	Phosphagenics Targeting Morphine Delivery Market
Contact Us

Web Site Design & Business Hosting by Simple I.D.